PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för SCH772984. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

21 hits

Bibliografisk träff 2021-12-01

GIT1 overexpression promotes epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma.

Wang G, Bai X, Jiang G, Jin S, Wang Q, Wang A, Peng R, Ke A, Bai D.

Bioengineered · research support, non-u.s. gov't; research-article; journal article · DOI 10.1080/21655979.2020.1855914

Bibliografisk träff 2021-06-01

Norcantharidin induces G2/M arrest and apoptosis via activation of ERK and JNK, but not p38 signaling in human renal cell carcinoma ACHN cells.

Huang S, Tuergong G, Zhu H, Wang X, Weng G, Ren Y.

Acta Pharm · journal article · DOI 10.2478/acph-2021-0012

Bibliografisk träff 2021-03-11

Extracellular signal-regulated kinase inhibition prevents venous adaptive remodeling via regulation of Eph-B4.

Guo Y, Zhu F, Zhang X, Wu G, Fu P, Yang J.

Vascular · journal article · DOI 10.1177/1708538121999854

Bibliografisk träff 2021-03-01

Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo.

Hicks HM, McKenna LR, Espinoza VL, Pozdeyev N, Pike LA, Sams SB, LaBarbera D, Reigan P, Raeburn CD, E Schweppe R.

Mol Carcinog · journal article; research support, n.i.h., extramural · DOI 10.1002/mc.23284

Bibliografisk träff 2021-02-23

Rap2B promotes the proliferation and migration of human glioma cells via activation of the ERK pathway.

Shi G, Zhang Z.

Oncol Lett · research-article; journal article · DOI 10.3892/ol.2021.12575

Bibliografisk träff 2020-11-24

pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.

Ray P, Dutta D, Haque I, Nair G, Mohammed J, Parmer M, Kale N, Orr M, Jain P, Banerjee S, Reindl KM, Mallik S, Kambhampati S, Banerjee SK, Quadir M.

Mol Pharm · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.molpharmaceut.0c00499

Bibliografisk träff 2020-10-01

[Study on mechanisms of interleukin-17A regulating the expressions of interleukin-1β and interleukin-23 in mouse keratinocytes].

Li YS, Zhang XR, Yu MJ, Hu XH, Yang JC, Huang Y, Luo GX, He WF.

Zhonghua Shao Shang Za Zhi · journal article · DOI 10.3760/cma.j.cn501120-20200619-00315

Bibliografisk träff 2020-07-31

JuBei Oral Liquid Induces Mitochondria-Mediated Apoptosis in NSCLC Cells.

Pan Z, Chen Q, Zheng X, Wang K, Duan Y, Xiao K, Jia Z, Ding X.

Onco Targets Ther · research-article; journal article · DOI 10.2147/ott.s254464

Bibliografisk träff 2020-07-08

Splenectomy enhances the Ly6C<sup>low</sup> phenotype in hepatic macrophages by activating the ERK1/2 pathway during liver fibrosis.

Zheng Z, Wang H, Li L, Zhang S, Zhang C, Zhang H, Ji F, Liu X, Zhu K, Kong G, Li Z.

Int Immunopharmacol · journal article · DOI 10.1016/j.intimp.2020.106762

Bibliografisk träff 2019-07-16

Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2.

Pegram LM, Liddle JC, Xiao Y, Hoh M, Rudolph J, Iverson DB, Vigers GP, Smith D, Zhang H, Wang W, Moffat JG, Ahn NG.

Proc Natl Acad Sci U S A · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1073/pnas.1906824116

Bibliografisk träff 2019-05-04

Hydroxysafflor yellow A inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways.

Jiang M, Zhou LY, Xu N, An Q.

Thorac Cancer · research-article; journal article · DOI 10.1111/1759-7714.13019

Bibliografisk träff 2019-03-26

Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer.

Ray P, Nair G, Ghosh A, Banerjee S, Golovko MY, Banerjee SK, Reindl KM, Mallik S, Quadir M.

J Cell Commun Signal · research-article; journal article · DOI 10.1007/s12079-019-00514-w

Bibliografisk träff 2018-05-31

Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2.

Heightman TD, Berdini V, Braithwaite H, Buck IM, Cassidy M, Castro J, Courtin A, Day JEH, East C, Fazal L, Graham B, Griffiths-Jones CM, Lyons JF, Martins V, Muench S, Munck JM, Norton D, O'Reilly M, Palmer N, Pathuri P, Reader M, Rees DC, Rich SJ, Richardson C, Saini H, Thompson NT, Wallis NG, Walton H, Wilsher NE, Woolford AJ, Cooke M, Cousin D, Onions S, Shannon J, Watts J, Murray CW.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.8b00421

Bibliografisk träff 2017-12-27

MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.

Räsänen K, Dang KX, Mustonen H, Ho TH, Lintula S, Koistinen H, Stenman UH, Haglund C, Stenman J.

Mol Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/1878-0261.12160

Bibliografisk träff 2017-10-09

Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling.

Zhou J, Zhao T, Ma L, Liang M, Guo YJ, Zhao LM.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.21704

Bibliografisk träff 2017-07-06

ErbB2 signaling epigenetically suppresses microRNA-205 transcription via Ras/Raf/MEK/ERK pathway in breast cancer.

Hasegawa T, Adachi R, Iwakata H, Takeno T, Sato K, Sakamaki T.

FEBS Open Bio · research-article; journal article · DOI 10.1002/2211-5463.12256

Bibliografisk träff 2016-04-26

Analgesic effect and possible mechanism of SCH772984 intrathecal injection on rats with bone cancer pain.

Bian J, Zhu S, Ma W, Li C, Ashraf MA.

Saudi Pharm J · research-article; journal article · DOI 10.1016/j.jsps.2016.04.017

Bibliografisk träff 2016-02-01

Dissecting Therapeutic Resistance to ERK Inhibition.

Jha S, Morris EJ, Hruza A, Mansueto MS, Schroeder GK, Arbanas J, McMasters D, Restaino CR, Dayananth P, Black S, Elsen NL, Mannarino A, Cooper A, Fawell S, Zawel L, Jayaraman L, Samatar AA.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-15-0172

Bibliografisk träff 2014-09-07

A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics.

Chaikuad A, Tacconi EM, Zimmer J, Liang Y, Gray NS, Tarsounas M, Knapp S.

Nat Chem Biol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/nchembio.1629

Bibliografisk träff 2014-08-20

Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.

Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A.

Mol Cancer · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1186/1476-4598-13-194

Bibliografisk träff 2013-07-01

ERK pathway inhibitors: how low should we go?

Nissan MH, Rosen N, Solit DB.

Cancer Discov · journal article · DOI 10.1158/2159-8290.cd-13-0245